BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 1712606)

  • 21. [Advanced germinal tumors of the testicle: clinical experience with cisplatin, bleomycin and vinblastine (PVB) or etoposide (BEP)].
    Alonso Curbera G; González-Manzano R; Aramendía Beitia JM; Martínez Monge R; Agüera Fernández L; Rebollo Liceaga J
    Rev Med Univ Navarra; 1993; 38(1):13-8. PubMed ID: 8711305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy.
    Price P; Hogan SJ; Bliss JM; Horwich A
    Eur J Cancer; 1990 Apr; 26(4):453-7. PubMed ID: 1694087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.
    Kawai K; Ando S; Hinotsu S; Oikawa T; Sekido N; Miyanaga N; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Jul; 36(7):425-31. PubMed ID: 16790450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).
    Peckham MJ; Barrett A; Liew KH; Horwich A; Robinson B; Dobbs HJ; McElwain TJ; Hendry WF
    Br J Cancer; 1983 May; 47(5):613-9. PubMed ID: 6189504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
    Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
    Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin.
    Lauritsen J; Kier MG; Bandak M; Mortensen MS; Thomsen FB; Mortensen J; Daugaard G
    J Clin Oncol; 2016 May; 34(13):1492-9. PubMed ID: 26903578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
    de Wit R; Stoter G; Sleijfer DT; Neijt JP; ten Bokkel Huinink WW; de Prijck L; Collette L; Sylvester R
    Br J Cancer; 1998 Sep; 78(6):828-32. PubMed ID: 9743309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Length of follow-up in teratomas--results of a modification of Einhorn's regime in testicular teratomas.
    Wilkins M; Williams MV; Mort D; James KW; Webster DJ
    Eur J Surg Oncol; 1986 Jun; 12(2):153-7. PubMed ID: 2423374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis.
    Germá Lluch JR; Seguí Palmer MA; Climent Durán MA; Blanco Guerrero R; Fernández Sagarra A; Villavicencio H; Solé Balcells FJ
    Eur Urol; 1992; 21(4):287-93. PubMed ID: 1333957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
    Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis following chemotherapy for metastatic malignant teratoma.
    Horwich A; Easton D; Husband J; Nicholas D; Peckham MJ
    Br J Urol; 1987 Jun; 59(6):578-83. PubMed ID: 2446691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
    Husband DJ; Green JA
    Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The late effects of cis-platinum on renal function.
    Hamilton CR; Bliss JM; Horwich A
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):185-9. PubMed ID: 2467807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
    Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
    Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
    Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.